These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20016845)

  • 21. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
    Chrysant SG; Ibrahim M
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
    Sharma M; Sharma DR; Singh V; Panwar RB; Hira HS; Mohan B; Kumar N; Sharma SK; Gupta R
    Vasc Health Risk Manag; 2006; 2(1):87-93. PubMed ID: 17319473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of extended-release niacin with laropiprant in high-risk patients.
    ; Landray MJ; Haynes R; Hopewell JC; Parish S; Aung T; Tomson J; Wallendszus K; Craig M; Jiang L; Collins R; Armitage J
    N Engl J Med; 2014 Jul; 371(3):203-12. PubMed ID: 25014686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
    Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
    J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction.
    Bregar U; Jug B; Keber I; Cevc M; Sebestjen M
    Heart Vessels; 2014 May; 29(3):313-9. PubMed ID: 23712600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecule of the Month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides.
    Felts AS
    Curr Top Med Chem; 2008; 8(14):1310. PubMed ID: 18928015
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
    Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended-release niacin/laropiprant for lipid management: observational study in clinical practice.
    Steinhagen-Thiessen E; Dänschel W; Buffleben C; Smolka W; Pittrow D; Hildemann SK
    Int J Clin Pract; 2013 Jun; 67(6):527-35. PubMed ID: 23437867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.
    Bays H; Shah A; Dong Q; McCrary Sisk C; Maccubbin D
    Int J Clin Pract; 2011 Apr; 65(4):436-45. PubMed ID: 21401833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
    McKenney J; Bays H; Koren M; Ballantyne CM; Paolini JF; Mitchel Y; Betteridge A; Kuznetsova O; Sapre A; Sisk CM; Maccubbin D
    J Clin Lipidol; 2010; 4(2):105-112.e1. PubMed ID: 21122637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
    Brinton EA; Triscari J; Brudi P; Chen E; Johnson-Levonas AO; Sisk CM; Ruck RA; MacLean AA; Maccubbin D; Mitchel YB
    Lipids Health Dis; 2016 Jul; 15(1):116. PubMed ID: 27405296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of flushing due to niacin and abolition of these effects.
    Sood A; Arora R
    J Clin Hypertens (Greenwich); 2009 Nov; 11(11):685-9. PubMed ID: 19878384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1.
    Lai E; De Lepeleire I; Crumley TM; Liu F; Wenning LA; Michiels N; Vets E; O'Neill G; Wagner JA; Gottesdiener K
    Clin Pharmacol Ther; 2007 Jun; 81(6):849-57. PubMed ID: 17392721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term effects of extended-release niacin with and without the addition of laropiprant on endothelial function in individuals with low HDL-C: a randomized, controlled crossover trial.
    Nasser Figueiredo V; Vendrame F; Colontoni BA; Quinaglia T; Roberto Matos-Souza J; Azevedo Moura F; Coelho OR; de Faria EC; Sposito AC
    Clin Ther; 2014 Jun; 36(6):961-6. PubMed ID: 24768191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
    Bays HE; Ballantyne C
    Curr Opin Lipidol; 2009 Dec; 20(6):467-76. PubMed ID: 19779335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
    Schulz I
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):344-59. PubMed ID: 16767301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mechanism and mitigation of niacin-induced flushing.
    Kamanna VS; Ganji SH; Kashyap ML
    Int J Clin Pract; 2009 Sep; 63(9):1369-77. PubMed ID: 19691622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.